Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

Chang Gung Medical Foundation

Status: Completed

Conditions: Hepatocellular Carcinoma Resectable

Study type: Observational

Funder types: Other

Identifiers

NCT04177316

201801969B0

Details and patient eligibility

About

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Full description

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number.

Enrollment: 92 patients

Sex: All

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies

Exclusion criteria

history of different malignant disease. subjects cannot be treated with curative surgery.

Trial design

92 participants in 2 patient groups

hypermethylation

Description:

The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.

hypomethylation/no change

Description:

The hypomethylation were defined as differential methylation status of tumor- normal \<5%